Detected ·
Vaderis Therapeutics AG
$152M—
Vaderis Therapeutics AG raised $152M in a Series B round. The Swiss clinical-stage biotech is developing engasertib, a potential first treatment for hereditary hemorrhagic telangiectasia (HHT), a rare genetic vascular disease. EQT Life Sciences participated in the round.
- Website
- vaderis.com
- Amount
- $152 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-11 16:09:08 UTC
- Signal ID
- 07455037-9456-4de3-9b2c-0ed8ca2da1d3
As the API returns it
{
"id": "07455037-9456-4de3-9b2c-0ed8ca2da1d3",
"created_at": "2026-08-11T16:09:08.132371Z",
"company_name": "Vaderis Therapeutics AG",
"company_website_url": "vaderis.com",
"company_linkedin_url": "https://www.linkedin.com/company/vaderis-therapeutics-ag",
"event_type": "funding",
"funding_amount": 152000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Vaderis Therapeutics AG raised $152M in a Series B round. The Swiss clinical-stage biotech is developing engasertib, a potential first treatment for hereditary hemorrhagic telangiectasia (HHT), a rare genetic vascular disease. EQT Life Sciences participated in the round.*"
}